experiment
adenovirusbas
vaccin
vector
promis
altern
convent
vaccin
platform
particular
human
adenoviru
serotyp
vector
wellcharacter
develop
sever
infecti
diseas
model
includ
influenza
hepat
c
dengu
viral
hemorrhag
fever
virus
sever
candid
demonstr
uniqu
protect
efficaci
gener
robust
immun
respons
anim
model
clinic
trial
preexist
immun
howev
frequent
human
popul
associ
undesir
clinic
outcom
suspens
clinic
trial
one
promis
altern
develop
evalu
rare
human
chimpanze
mammalian
adenoviru
vector
low
seropreval
human
chimer
simian
adenoviru
vector
protect
mice
lethal
ebolaviru
challeng
gener
robust
tcell
respons
glycoprotein
nonhuman
primat
bovin
adenoviru
vaccin
previous
demonstr
success
protect
avian
influenza
viru
challeng
mice
abl
escap
preexist
neutral
antibodi
similarli
porcin
adenoviru
vector
success
sever
swine
vaccin
studi
classic
swine
fever
pseudorabi
viru
vaccin
abl
evad
preexist
immun
provid
longterm
protect
pig
antigen
profil
report
vivo
efficaci
anim
vaccin
make
vector
promis
altern
adenoviru
vector
human
administr
due
genet
divers
avail
sever
significantli
differ
isol
avian
influenza
virus
provid
valuabl
challeng
diseas
model
evalu
broad
immun
respons
gener
potenti
adenoviru
vector
extern
hemagglutinin
ha
glycoprotein
mediat
receptor
bind
fusion
gener
strong
antibodi
cellmedi
immun
respons
directli
assay
provid
use
comparison
adenoviru
platform
highli
pathogen
avian
influenza
virus
spread
throughout
domest
aquat
bird
popul
south
east
asia
world
health
organ
confirm
clinic
case
crosstransmiss
human
despit
limit
incid
humantohumantransmiss
high
mortal
rate
continu
evolut
viru
repres
concern
futur
influenza
pandem
emerg
pandem
swinelik
influenza
viru
isol
earli
highlight
need
gener
crossprotect
last
immun
respons
diverg
human
zoonot
influenza
virus
addit
evalu
differ
adenoviru
platform
develop
improv
influenza
vaccin
would
also
help
better
prepar
emerg
pandem
virus
could
reduc
impact
infect
public
health
studi
evalu
protect
efficaci
follow
lethal
homolog
challeng
replicationincompet
porcin
adenoviru
vector
express
ha
gene
influenza
isol
immunogen
ha
success
previou
vaccin
suggest
avian
influenza
may
good
compar
model
evalu
efficaci
similar
vector
previou
studi
show
exhibit
crossreact
neutral
antibodi
addit
neutral
lowest
dilut
randomli
select
human
sera
order
address
neutral
extend
number
human
sera
human
ig
made
pool
sera
individu
evalu
use
control
neutral
highest
dilut
mgml
human
ig
contrast
neutral
detect
mgml
lowest
dilut
test
previou
studi
show
littl
crossreact
cellmedi
immun
respons
optim
express
cassett
contain
codonoptim
insert
homolog
recombin
replicationincompet
vector
contain
delet
gene
describ
vaccin
also
develop
parallel
control
compar
level
protect
immun
respons
express
vaccin
evalu
vribl
hek
mous
cell
figur
balbc
mice
also
vaccin
viru
particl
vp
vivo
express
muscl
tissu
detect
day
postimmun
figur
robust
antibodi
respons
import
prevent
influenza
viru
infect
abil
vaccin
gener
humor
immun
respons
follow
immun
assay
detect
haspecif
antibodi
hemagglutin
inhibit
hi
neutral
antibodi
nab
titr
balbc
mice
vaccin
vpmous
develop
hi
nab
antibodi
respons
monitor
serum
collect
day
postimmun
sampl
treat
receptordestroy
enzym
rde
follow
complement
inactiv
next
day
hi
assay
perform
use
serial
dilut
treat
serum
combin
viru
hors
red
blood
cell
detect
inhibit
cell
agglutin
serum
antibodi
reciproc
highest
dilut
agglutin
red
blood
cell
score
hi
antibodi
titr
hi
titr
detect
respect
statist
differ
two
vaccin
figur
presenc
neutral
antibodi
inhibit
activ
infect
also
evalu
measur
humor
respons
serial
dilut
treat
serum
incub
pfuwel
viru
cell
monitor
presenc
absenc
cytopath
effect
cpe
use
light
microscop
highest
serum
dilut
exhibit
cpe
score
posit
neutral
antibodi
titr
report
reciproc
dilut
nab
titr
reciproc
dilut
observ
vaccin
day
respect
figur
increas
neutral
antibodi
respons
follow
vaccin
statist
signific
day
p
rel
order
assess
antibodi
titr
immedi
challeng
mice
vaccin
differ
dose
vaccin
serum
obtain
postimmun
hi
reciproc
titr
vaccin
detect
vpmous
dose
respect
figur
vaccin
similar
hi
antibodi
titr
dose
signific
differ
detect
p
base
clinic
data
refer
hi
antibodi
titr
recommend
influenza
vaccin
candid
minimum
level
confer
fifti
percent
protect
human
vaccin
met
requir
dose
prior
challeng
serum
sampl
averag
nab
titr
reciproc
dilut
vpmous
respect
figur
vaccin
gener
nab
titr
vpmous
respect
although
strong
antibodi
respons
import
immedi
longterm
protect
influenza
virus
induct
earli
cellular
immun
respons
follow
vaccin
may
enhanc
clearanc
virusinfect
cell
follow
influenza
viru
infect
tcell
respons
assay
use
enzymelink
immunosorb
spot
elispot
assay
detect
secret
interferon
gamma
activ
lymphocyt
splenocyt
obtain
mice
vaccin
day
vpmous
cell
restimul
pool
overlap
peptid
correspond
entir
protein
peptid
correspond
immunodomin
ha
iystvassl
conserv
influenza
viru
epitop
evalu
alongsid
unrel
control
peptid
tyqrtralv
nucleoprotein
mice
vaccin
spotform
cell
sfc
per
million
splenocyt
detect
day
respect
figur
immun
vaccin
gener
sfcmillion
respect
number
sfcmillion
splenocyt
detect
day
statist
signific
vaccin
p
immunodomin
epitop
also
stimul
strongest
tcell
respons
day
vaccin
compar
vaccin
mice
gener
averag
sfcmillion
day
wherea
sfcmillion
detect
mice
time
point
figur
p
day
averag
respons
follow
stimul
immunodomin
epitop
sfcmillion
immun
mice
respect
p
tcell
respons
detect
day
postimmun
respect
restimul
splenocyt
immun
mice
np
control
peptid
repeatedli
gener
less
sfcmillion
cellular
respons
follow
vaccin
character
detect
rel
frequenc
peptidespecif
cell
express
flow
cytometri
splenocyt
harvest
ten
day
postimmun
restimul
vitro
immunodomin
peptid
unrel
np
zgp
telrtfsi
zair
ebolaviru
glycoprotein
control
peptid
cell
stain
antimous
fluorescein
isothiocyan
antimous
phycoerythrin
frequenc
posit
tcell
percent
respect
figur
cell
stimul
control
peptid
np
zgp
show
frequenc
posit
tcell
equal
percent
respect
result
suggest
vaccin
stimul
robust
immun
respons
mice
faster
compar
strength
earli
detect
tcell
respons
day
postvaccin
vaccin
suggest
may
good
candid
immedi
administr
prior
follow
suspect
exposur
viru
success
rapid
vaccin
regimen
evalu
two
part
first
overal
surviv
second
total
viral
load
lung
tissu
determin
assay
balbc
mice
challeng
lethal
dose
viru
day
postvaccin
lung
harvest
day
postinfect
although
mice
challeng
day
postvaccin
surviv
lethal
challeng
figur
anim
challeng
day
postvaccin
experienc
significantli
greater
surviv
surviv
vaccin
surviv
less
sign
diseas
weight
loss
figur
p
vaccin
fulli
protect
minim
sign
diseas
administ
day
prior
challeng
figur
lung
viral
titr
significantli
lower
time
point
vaccin
compar
unvaccin
control
anim
figur
follow
vaccin
viru
titer
day
respect
vaccin
associ
significantli
lower
viral
load
anim
vaccin
day
compar
p
p
respect
vaccin
similar
day
p
surviv
also
assess
group
balbc
mice
vaccin
viru
particl
recombin
adenoviru
intramuscular
im
administr
challeng
day
later
lethal
homolog
viru
protect
clinic
sign
diseas
minim
weight
loss
full
surviv
observ
vpmous
dose
adbas
vaccin
figur
complet
surviv
also
observ
vaccin
dose
vpmous
vaccin
mice
either
asymptomat
milder
sign
diseas
weight
loss
compar
weight
loss
anoth
desir
characterist
influenza
vaccin
provid
longterm
protect
therefor
long
term
immun
evalu
mice
challeng
month
vaccin
order
determin
whether
protect
immun
respons
could
maintain
afford
full
protect
mice
challeng
viru
month
postimmun
wherea
mice
vaccin
succumb
figur
higher
hi
antibodi
titer
compar
respect
p
may
translat
directli
improv
surviv
observ
vaccin
nab
titer
figur
elisa
assay
also
perform
detect
total
igg
antibodi
titr
antigen
serum
obtain
mice
day
year
postvaccin
unvaccin
control
mice
figur
total
antibodi
titer
significantli
lower
vaccin
year
averag
higher
level
igg
antibodi
detect
vaccin
howev
differ
statist
signific
compar
p
current
replicationdefici
human
adenoviru
serotyp
vaccin
evalu
sever
pathogen
sever
candid
shown
induc
protect
immun
respons
emerg
reemerg
infecti
pathogen
ebola
avian
influenza
virus
complet
protect
longterm
memori
respons
also
report
differ
anim
model
howev
final
develop
vector
approv
human
vaccin
hamper
presenc
natur
preexist
immun
present
larg
fraction
human
popul
neutral
antibodi
porcin
adenoviru
detect
pool
immun
globulin
repres
thousand
human
sera
suggest
preexist
immun
vaccin
like
concern
human
applic
addit
document
compat
porcin
human
tissu
could
translat
vaccin
efficaci
low
toxic
human
develop
new
adenoviru
serotyp
also
increas
spectrum
possibl
applic
sequenti
vaccin
adenoviru
vector
eg
primeboost
second
adbas
vaccin
differ
agent
present
studi
compar
parallel
immun
respons
protect
gener
vector
similar
vector
use
avian
influenza
diseas
model
infect
vector
express
ha
antigen
abl
gener
quick
robust
immun
respons
find
support
rapid
induct
improv
immedi
protect
vaccin
compar
interestingli
vaccin
share
similar
vivo
express
suggest
increas
vaccin
efficaci
observ
may
due
specif
interact
immun
system
rather
enhanc
express
antigen
recent
studi
suggest
may
activ
differ
innat
immun
pathway
addit
offer
improv
longterm
protect
lethal
viru
challeng
higher
level
detect
antibodi
hi
assay
although
full
shortterm
day
surviv
observ
follow
vaccin
vpmous
dose
greater
weight
loss
observ
vaccin
compar
hi
nab
antibodi
titr
observ
clinic
outcom
suggest
may
incomplet
neutral
viru
follow
vaccin
perhap
explain
differ
level
protect
observ
follow
challeng
postvaccin
shown
level
neutral
antibodi
serum
decreas
time
follow
infect
follow
vaccin
exact
level
neutral
antibodi
correl
full
protect
infect
homolog
viru
still
uncertain
comparison
total
igg
antibodi
level
neutral
antibodi
titr
correl
better
earli
longterm
protect
similar
previous
describ
report
togeth
data
suggest
vector
addit
option
vector
could
sever
import
applic
includ
rapid
postexposur
protect
emerg
influenza
virus
infecti
agent
similar
studi
describ
vaccin
share
compar
protect
efficaci
viru
two
dose
vector
gener
similar
humor
cellmedi
immun
respons
abl
evad
preexist
neutral
antibodi
overal
protect
efficaci
offer
similar
one
month
postimmun
immun
respons
kinet
also
gener
compar
later
time
point
although
explor
current
studi
previou
studi
evalu
impact
preexist
immun
potenti
reus
vector
differ
pathogen
group
outbr
pig
high
neutral
antibodi
titr
vaccin
vaccin
vector
readministr
result
hepatotox
reduc
transgen
express
dose
particleskg
vector
also
bypass
preexist
immun
howev
sever
patholog
includ
liver
damag
indic
elev
transaminas
low
platelet
count
lymphocytopenia
observ
nonhuman
primat
administ
similar
dose
even
though
convent
vaccin
rel
success
influenza
infect
abil
adenovir
vector
rapidli
gener
strong
immun
respons
may
use
specif
applic
rapid
immun
health
care
worker
anticip
probabl
exposur
emerg
virul
pandem
viru
addit
strong
antibodi
respons
viru
surviv
cellular
respons
suggest
induct
earlier
tcell
respons
complement
develop
antibodi
respons
improv
protect
challeng
contribut
directli
toward
lower
viral
load
although
influenza
glycoprotein
high
antigen
variat
gener
faster
tcell
respons
vector
wellconserv
influenza
antigen
may
supplement
mismatch
antibodi
respons
may
improv
protect
wider
rang
influenza
virus
previou
studi
shown
vector
transduc
sever
human
cell
line
result
full
transgen
express
adenovir
coat
protein
addit
safeti
featur
wildtyp
replic
human
cell
suggest
replicationcompet
vector
would
easi
produc
high
titr
could
also
promis
vaccin
candid
nevertheless
perform
new
vaccin
vector
need
address
anim
speci
includ
nonhuman
primat
real
util
human
vaccin
predict
accur
overal
studi
support
complementari
role
cellular
immun
earli
infect
develop
porcin
adenovirus
human
vaccin
candid
anim
procedur
score
sheet
first
approv
anim
care
committe
anim
use
document
id
canadian
scienc
centr
human
anim
health
accord
guidelin
set
canadian
council
anim
care
human
embryon
kidney
hek
cell
madindarbi
canin
kidney
cell
mdck
mous
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
lglutam
sodium
pyruv
napyr
antibiot
fetal
porcin
retina
cell
express
human
adenoviru
porcin
adenoviru
larg
gene
maintain
minimum
essenti
medium
mem
alpha
supplement
fb
lglutam
napyr
nonessenti
amino
acid
hepe
buffer
salin
penicillinstreptomycin
hygromycin
b
bd
bioscienc
avian
influenza
strain
gener
provid
q
mai
le
hien
nguyen
nation
institut
hygien
epidemiolog
hanoi
vietnam
viru
propag
mdck
cell
cultur
viru
diluent
mem
bovin
serum
albumin
antibiot
contain
tpcktreat
trypsin
tpcktrypsin
titer
plaqu
assay
infecti
recombin
adenoviru
construct
propag
hek
cell
purifi
cesium
chlorid
densiti
gradient
full
complementari
dna
cdna
sequenc
hemagglutinin
gene
obtain
codon
optim
synthes
overlap
oligonucleotid
primer
previous
describ
gene
first
clone
plasmid
contain
cag
promot
gener
construct
express
cassett
excis
insert
two
shuttl
vector
system
clontech
vido
univers
saskatchewan
insert
express
cassett
replac
exist
cytomegaloviru
cmv
promot
cag
promot
result
construct
transfer
plasmid
also
modifi
includ
polyadenyl
signal
gener
hapolya
transgen
cassett
clone
replicationdefici
adenovir
vector
padenox
clontech
vido
univers
saskatchewan
padenoxha
gener
digest
padenox
home
endonucleas
iceuipiscei
ligat
cohes
end
use
dna
ligas
invitrogen
gener
homolog
recombin
escherichia
coli
strain
recbc
sbcbc
linear
paci
obtain
vaccin
hek
cell
transfect
linear
padenoxha
dna
calcium
phosphat
bd
bioscienc
solut
cell
cultur
appear
cytopath
effect
cpe
similarli
cell
transfect
ug
linear
dna
combin
lipofectin
invitrogen
cell
cultur
cpe
appar
amplifi
adenovirus
contain
cell
lysat
harvest
freezethaw
three
time
purifi
cscl
gradient
integr
transgen
cassett
confirm
ecori
restrict
digest
sequenc
dna
core
nation
microbiolog
laboratori
multipl
primer
set
total
viru
particl
vp
determin
total
infecti
particl
determin
use
antihexon
antibodi
adenox
rapid
titer
kit
clontech
vido
univers
saskatchewan
four
independ
vector
prepar
use
vaccin
total
infecti
particl
total
viral
particl
determin
adenoviru
vaccin
ratio
protein
express
vector
confirm
hek
vribl
cell
use
standard
western
blot
techniqu
evalu
vivo
express
group
balbc
mice
vaccin
vp
muscl
tissu
harvest
day
follow
immun
muscl
tissu
homogen
normal
per
gram
muscl
tissu
radioimmunoprecipit
ripa
buffer
express
vaccin
detect
load
muscl
tissu
group
balbc
charl
river
canada
vaccin
vp
recombin
adenoviru
intramuscular
im
administr
vaccin
dilut
administ
right
left
hind
limb
mice
anesthet
challeng
day
intranas
inocul
time
dose
viru
requir
obtain
surviv
lethal
dose
viru
diluent
viru
plaqu
form
unit
pfu
therefor
pfu
mice
monitor
day
follow
challeng
sign
diseas
includ
weight
loss
labor
breath
ruffl
fur
death
observ
accord
approv
score
chart
anim
procedur
approv
institut
anim
care
committe
nation
microbiolog
laboratori
nml
public
health
agenc
canada
phac
accord
guidelin
canadian
council
anim
care
infecti
work
perform
high
biocontain
laboratori
nmlphac
group
balbc
mice
vaccin
vp
vaccin
day
experi
bd
bioscienc
plate
coat
purifi
mous
incub
overnight
well
overlap
peptid
mimitop
australia
span
entir
protein
resuspend
overnight
dimethyl
sulfoxid
dmso
alloc
pool
matrix
format
spleen
harvest
day
postimmun
splenocyt
plate
cellswel
rpmi
supplement
fb
lglutamin
napyr
hepe
nonessenti
amino
acid
antibiot
restimul
peptid
pool
per
well
individu
peptid
repres
immunodomin
iystvassl
conserv
influenza
virus
epitop
also
evalu
along
neg
control
tyqrtralv
nucleoprotein
zgp
telrtfsi
zair
ebolaviru
glycoprotein
plate
incub
overnight
hour
wash
follow
day
accord
manufactur
instruct
aec
substrat
set
bd
bioscienc
use
develop
spot
form
interferon
gamma
secret
cell
spot
visual
count
use
elispot
plate
reader
aid
elispot
reader
cell
technolog
colombia
maryland
splenocyt
obtain
day
postvaccin
plate
cellswel
restimul
zgp
individu
peptid
dmem
supplement
fb
lglutamin
napyr
hepe
nonessenti
amino
acid
antibiot
golgistop
brefeldin
bd
bioscienc
cell
stimul
hour
stain
antimous
fluorescein
isothiocyan
minut
bd
cytofix
permwash
protocol
use
fix
permeabil
cell
accord
manufactur
instruct
follow
day
cell
stain
interferon
gamma
use
antimous
phycoerythrin
sampl
read
lsrii
flow
cytomet
bd
bioscienc
data
analyz
use
bd
facsdiva
softwar
bd
bioscienc
serum
detect
ha
specif
antibodi
neutral
hemagglutin
inhibit
assay
collect
mous
follow
immun
previous
describ
briefli
sampl
treat
receptordestroy
enzym
rde
ratio
accur
chemic
overnight
inactiv
follow
day
minut
start
dilut
twofold
serial
dilut
serum
done
roundbottom
microtit
plate
viru
diluent
mem
bsa
antibiot
mix
pfuwel
homolog
viru
incub
minut
hemagglutin
inhibit
hi
assay
twofold
serial
dilut
sampl
perform
phosphat
buffer
salin
pb
ad
vbottom
microtit
plate
four
hemagglutin
dose
homolog
ad
well
plate
incub
room
temperatur
one
hour
hors
red
blood
cell
erythrocyt
salin
ad
well
incub
minut
hemagglutin
titer
determin
reciproc
highest
dilut
red
blood
cell
agglutin
neutral
assay
serumviru
mixtur
ad
onto
subconflu
mdck
cell
flatbottom
microtit
plate
incub
minut
room
temperatur
viru
diluent
supplement
tpcktrypsin
ad
well
incub
hour
cell
monitor
presenc
absenc
cpe
use
light
microscop
highest
serum
dilut
exhibit
cpe
score
posit
neutral
antibodi
titer
report
reciproc
dilut
infecti
vitro
work
perform
high
contain
laboratori
nmlphac
enzymelink
immunosorb
assay
elisa
perform
evalu
total
igg
antibodi
present
serum
day
year
follow
vaccin
plate
nunc
coat
ugml
ha
antigen
overnight
follow
day
serial
tenfold
dilut
serum
ad
plate
incub
minut
room
temperatur
follow
three
wash
goat
antimous
conjug
hrp
appli
secondari
antibodi
minut
addit
three
wash
tmb
solut
ad
react
hrp
conjug
incub
dark
minut
reaction
stop
use
sulphur
acid
solut
absorb
detect
nm
endpoint
cutoff
determin
last
serum
dilut
greater
two
time
optic
densiti
neg
control
endpoint
titr
report
reciproc
first
serum
dilut
higher
cutoff
group
balbc
mice
vaccin
vpmous
dose
day
prior
challeng
viru
nine
anim
monitor
surviv
lung
tissu
blood
harvest
remain
mice
three
day
postinfect
viru
load
determin
tissu
cultur
infecti
dose
result
cytopath
effect
cpe
fifti
percent
cell
cultur
perform
ad
serial
dilut
homogen
lung
tissu
onto
mdck
cell
monitor
presenc
cpe
hour
titr
calcul
use
reed
muench
method
normal
per
gram
lung
tissu
graph
gener
use
graphpad
prism
data
analyz
statist
differ
perform
unpair
test
oneway
analysi
varianc
anova
appropri
differ
mean
raw
valu
among
treatment
group
consid
signific
p
